A traditional Chinese medicine pharmacy in Weinan City, in China’s northwest Shaanxi Province. The overall industry has stalled, with only 17 out of 68 TCM makers recording year-on-year growth in revenue in the first half of 2020. Photo: Xinhua
Two Shenzhen-listed makers of traditional Chinese medicine (TCM), Shijiazhuang Yiling Pharmaceutical and Tianjin Chase Sun Pharmaceutical, have reaped stunning gains this year, riding on endorsements by the public face of China’s successful fight against the coronavirus pandemic.
Yiling reported a 57 per cent jump in net profit to 714 million yuan (US$106 million) for the first half of 2020, while its stock price surged by as much as 245 per cent between January and mid April, hitting its highest level since it went public in 2011. Chase Sun recorded 2.8 billion yuan in revenue for the first half, a 22 per cent increase compared with the same period last year.
Their fortunes came even as growth in the overall TCM industry stalled, with only 17 out of 68 TCM makers listed in China recording year-on-year growth in revenue in the first half of 2020, according to companies’ earnings reports.
Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China.
Behind Yiling and Chase Sun’s success is their close association with Zhong Nanshan, a top mainland Chinese medical expert famous for leading the country’s coronavirus containment efforts. A pulmonologist who has also studied in the UK, Zhong is a supporter of TCM and has frequently recommended the use of traditional remedies for treating coronavirus patients.
Yiling was founded in 1992 by TCM practitioner Wu Yiling, who is famous for developing a concoction of leech, whole scorpion, centipede, soil beetle and cicada slough used to treat cardiovascular diseases.
© Provided by South China Morning Post
A pulmonologist who has also studied in the UK, Zhong Nanshan is a supporter of TCM. Photo: Handout
Both Wu and Zhong are academicians at the Chinese Academy of Engineering, the highest academic title conferred by Beijing to engineers and scientists, and have collaborated since at least 2015, when Wu invited Zhong to join a 460 million yuan research lab set up for academicians by his company. In 2016, they co-founded a research centre to tackle lung diseases using TCM in the southern city of Guangzhou.
While his collaboration with Yiling is focused on research, Zhong’s association with Chase Sun has more to do with business. In April 2012, a Guangzhou-based medical foundation led by Zhong invested 3.5 million yuan in a pharmaceutical company along with Chase Sun, which invested 5 million, according to Tianyancha, a public database of business records.
Zhong has since sat on the board of the company along with Yao Xiaoqing, Chase Sun’s chairman. Founded in 1996, Chase Sun transferred a controlling stake in 2019 to the State-owned Assets Supervision and Administration Commission of Chengdu, and has become a state-owned company affiliated with the city in Southwest China.
Zhong, Yiling and Chase Sun did not reply